tirzepatide fda news approves new version of diabetes drug Mounjaro to be sold for weight loss FDA approves tirzepatide (Zepbound) injection

PMID: 40243461

On average, participants experienced a 15% reduction in their body weight over a period of 68 weeks

Brain 134(5):12931314 Sta M, Sylva-Steenland RMR, Casula M, De Jong JMBV, Troost D, Aronica E, Baas F (2011) Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation

you brand and distribute Fastest 2026 route to market for distributors entering the GLP-1 injectable segment for the first time Dossier transferable for regulatory filing in your target market, no duplicate R&D spend Private label / white-label Manufacturers validated semaglutide injectable reformatted under your brand identity and packaging design Lowest MOQ option is suitable for regional distributors and new market entrants in 2026 Custom labeling, patient-information leaflets, and carton artwork in your local language and regulatory format

While DPP-4 expression is significantly increased in patients with obesity and T2DM, the incretin effect is markedly impaired